Stock Comparison

ADAP vs LLY

Adaptimmune Therapeutics PLC vs Eli Lilly and Co

The Verdict

Dead heat. Both scored 0.5/10.

ADAP

Adaptimmune Therapeutics PLC

0.5

out of 10

Distressed

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$17M

Market Cap

$965.0B

0.0

P/E Ratio

52.6

-260.8%

Profit Margin

N/A

-163.7%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

0.5

DVR Score

0.5

The Deep Dive

ADAP0.5/10

Adaptimmune's score has plummeted due to a critical and rapid deterioration in its financial and operational status. The share price has collapsed by 90% since the last analysis, now at $0.0022 with an effective $0.00B market cap, signaling imminent failure. Most critically, the company is severely delinquent, having missed Q2, Q3, Q4 2025, and Q1 2026 earnings reports. This strongly indicates the...

Full ADAP Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.